Date

11-13-2025

Department

School of Behavioral Sciences

Degree

Doctor of Philosophy in Psychology (PhD)

Chair

Laura Rolen

Keywords

lecanemab monoclonal antibody infusion therapy, reminiscence therapy, beta amyloid, cognitive decline, anxiety, depression, quality of life, Alzheimer’s dementia, Christian servanthood

Disciplines

Psychology

Abstract

This case study examined whether a 12-month combined therapy (RT-L), which includes reminiscence therapy and lecanemab monoclonal antibody infusion therapy, will clear beta amyloid accumulation in the brain, slow cognitive decline, decrease depression, reduce anxiety, and increase the quality of life in a participant with mild cognitive impairment due to early Alzheimer’s dementia. The sample included one White female (age = 68) with mild cognitive impairment due to early Alzheimer’s disease who is currently being treated by a geriatrician at a facility in the Midwest. The outpatient treatment included a lecanemab antibody infusion of 10mg/kg every two weeks for 12 months and 8 sessions of reminiscence therapy. The beta amyloid was measured using positron emission tomography (PET) scans. Cognitive functioning, anxiety, depression, and quality of life were assessed using the Montreal Cognitive Assessment, Hamilton Anxiety Scale, Cornell Scale for Depression in Dementia, and Quality of Life–Alzheimer's Disease. A post-treatment 60-minute interview with the participant was conducted. The study compared scores before and after RT-L and analyzed the participant's experiences, perceptions, and behaviors to identify patterns related to biopsychosocial changes and enhance biopsychosocial interventions. The results showed a reduction in cognitive decline, depression, and anxiety, and improvements in quality of life, despite no changes in beta amyloid levels.

Download

Included in

Psychology Commons

Share

COinS